Robert A Hromas, MD, FACP
Senior Director for Drug Development, Mays Cancer Center
Professor, Hematology-Oncology, Department of Medicine
Dr. Hromas was the Dean at the Long School of Medicine at the UT San Antonio Health Science Center campus (UT Health San Antonio) until 2026. Prior to that, he was Chair of the Department of Medicine at the University of Florida, where he was also Vice President of the University of Florida Physicians Clinical Practice Association, and a member of the University of Florida Health Hospital Executive Board. He has personally trained 29 graduate students or fellows, most of which have entered academic careers, and 21 junior faculty, almost all of which have obtained tenure, with three obtaining Hematology-Oncology Division Chief Positions and two Chairs of Medicine. He has served on editorial boards of Blood and Stem Cells. He has won numerous teaching and patient care awards, including the Indiana University Humanism in Medical Education Award, the Indiana University Board of Trustees Outstanding Teacher Award, and the People Living Through Cancer Caring Award. He has served as Chair of Scientific Affairs for the American Society of Hematology, and as one of their congressional and media representatives. He has served as a full member of the Liaison Committee on Medical Education, the nation’s medical school accrediting body. He has published over 200 research papers, been continuously funded by the National Institutes of Health for over three decades and has chaired multiple NIH and American Cancer Society study sections. He has multiple patents and has co-founded two biotechnology companies, Abfero and Dialectic Therapeutics, both with compounds in phase 2 clinical trials. His laboratory has isolated and characterized multiple novel cytokines and several DNA mutations leading to leukemia. He has also identified several key components of DNA repair pathways that can be targeted in BRCA-deficient cancers. He is the author of the Harper-Collins business leadership book, Einstein’s Boss- 10 Rules for Leading Genius. For these and other accomplishments he has been elected to the American Society of Clinical Investigation, Association of Professors of Medicine, the American Clinical and Climatologic Association, and the Association of American Physicians.
-
Professional Background
Education
- Clinical Hematology Fellow - University of Washington and Fred Hutchinson Cancer Research Center
- Post-Doctoral Research Fellowship under Ken Kaushansky, MD on The Transcriptional Regulation of Hematopoiesis - Department of Internal Medicine, University of Washington University of Washington, Seattle, WA
- Resident, Internal Medicine, Clinical Investigator Pathway - University of Iowa Hospital, Iowa City, IA
- Post-Doctoral Research Fellowship under Gordon Ginder, MD on The Regulation of Class I HLA Gene Expression - University of Iowa, Department of Internal Medicine, Iowa City, IA
- Post-Doctoral Research Fellowship under Brian Van Ness, PhD on The Regulation of Immunoglobulin Gene Expression - University of Iowa, Department of Biochemistry, Iowa City, IA
- Doctor of Medicine (MD) - The University of Texas Medical School at Houston, TX, Alpha Omega Alpha (third year).
- Bachelor of Science - Biology - Wheaton College, Wheaton, IL, Magna Cum Laude
Highlights
Licensure and Certifications
- State of Texas Medical License
- Specialty Certification: American Board of Internal Medicine
- Subspecialty Certification: Hematology, American Board of Internal Medicine
Honors
2024 US News & World Report ranked UT Health San Antonio 51st in the world for Clinical Medicine (34th in north America) and 12th in the world for normalized Citation Impact (citations divided by research FTE)
2024 Nature Journal ranked UT Health San Antonio as the 6th fastest growing research institution on the US
2023 Convocation Speaker, Medical College of Wisconsin
2018 UT Health San Antonio runner-up for AAMC Spencer Foreman Award for Outstanding Community Service
2016 Association of American Medical Colleges Council of Deans Fellowship
2016 Golden Apple for Best Basic Science Course, Hematology, UF College of Medicine
2014 American Clinical and Climatological Association election
2011,14 Golden Apple Award for Best Clinical Teaching Department, Medicine, UF College of Medicine
2012 Association of American Physicians election
2011 Association of Professors of Medicine election
2007-10 Best Doctors in America
2006 UNM Department of Internal Medicine Senior Faculty Outstanding Research Award
2006 Albuquerque Magazine Top Docs – Hematology
2005 Fellow of the American College of Physicians
2005 UNM Department of Internal Medicine Outstanding Clinical Faculty Award
2005 UNM Hospital Physician Appreciation Award, given annually to the physician who made the most contributions to the UNM Hospital
2005 New Mexico State People Caring Award from People Living Through Cancer
2003 Graduation Banquet Speaker, Indiana University School of Medicine, elected by the class of ‘03
2002 Indiana University Board of Trustees Outstanding Teacher Award
- Nominated by the School of - Medicine faculty and students
- Awarded for the IU system Board of Trustees2002 American Society of Clinical Investigation election
2001 Humanism in Medical Education Award
- Best example of a physician mentor
- Elected by the Indiana University medical students1999 Stohlman Scholar of the Leukemia and Lymphoma Society of America
1995 Central Society for Clinical Research election
1994 Leukemia and Lymphoma Society Scholar Award
1991 Midwest Blood Club Annual Lectureship: "Oncogenes"
1984 Internal Medicine Outstanding Medical Student, Class of 1984, University of Texas Medical School at Houston
1983 Alpha Omega Alpha National Medical Honor Society, Junior Year University of Texas Medical School at Houston
1982 Texas Medical Association Louise Barekman Memorial Foundation Scholarship
1981 Medical Student Research Fellowship, MD Anderson Hospital and Tumor Institute
- Department of Developmental Therapeutics
- Supervisor, Bart Barlogie, MD1981 Freshman Academic Excellence Award, the University of Texas Medical School at Houston
Appointments
- 2018 - Medical Executive Committee member - University Health, San Antonio
- 2011 - Director of Medicine service lines - University of Florida Health Shands Teaching Hospital
- 2003 - Oncology Physician-In-Chief - University of New Mexico Hospital, Albuquerque, NM.
- 2003 - Director of Oncology Services - University of New Mexico Hospital, Albuquerque, NM
- 2003 - Chief of Hematology-Oncology - Veteran’s Administration Hospital, Albuquerque, NM
- 2003 - Director, Oncology Service Line - Lovelace Sandia Health System Hospitals, NM.
- 2003 - Lovelace Sandia Health System Hospitals, NM. - Supervised cancer care at 4 Lovelace Sandia community hospitals
-
-
Research & Grants
Grants
Active
- CPRIT Individual Investigator grant RP220269, MiR223-3p Suppression of BRCA1-Mutant Oncogenesis, PI- R. Hromas, total costs $889,587 over 3 yrs, 5-1-22 to 4-30-26.
NIH RO1 CA205224 (successful renewal), EEPD1 Repair of Stressed Replication Forks, 1-15-23 to 12-15-27. Direct Costs $237,000 per annum. PI: R. Hromas.
US Department of Commerce National Institute of Standards and Technology Financial Assistance Award 60NANB24D117, Medicinal Chemistry Infrastructure for Hepatic Steatosis Therapeutic Development, Total Cost $963,000. 5-4-24 to 5-3-25, PI- R. Hromas.
NIH PO1 CA275717, Regulation of BRCA-dependent genome repair via the 53BP1 axis, Annual direct costs- $1.89 M, PI-Sung, 7-1-24 to 6-30-28. Chromosome and Replication Analysis Core, PI-R. Hromas, Annual direct costs- $175,000.
Completed
Health Resources and Services Administration 1 CE1HS52902‐01‐00, Medicinal Chemistry Infrastructure for Hepatic Steatosis Therapeutic Development, Total Costs $1,000,000, 9-22-23 to 9-21-24.
NIH RO1 CA205224, EEPD1 Repair of Stressed Replication Forks, 6-1-16 to 5-31-21. Direct Costs $228,750 per annum. PI: R. Hromas
NIH RO1 GM109645, Mechanisms of Chromosomal Translocations, 7-1-15 to 6-30-19. Direct Costs $198,000 per annum. PI- R. Hromas.
NIH RO1 GM084020 “Metnase, PIKK, and RPA Roles in DNA Damage and Replication Stress
Responses,” 9-1-13 to 8-31-17, Direct costs $200,000 per annum. PI: J. Nickoloff, Co-I: R. Hromas.
Bankhead-Coley Cancer Research Program 4BB19 “Targeting Histone Methylation for Triple-Negative breast cancer therapy,” 1-1-13 to 12-31-16. Direct Costs $200,000 per annum. PI- R. Hromas.
Leukemia and Lymphoma Society Translational Research Award, “Targeting Transposase Domains for Leukemia Therapy,” 10-1-12 to 9-31-16, Direct costs $200,000 per annum. PI- R. Hromas.
NIH RO1 CA139429, “Epigenetic Control of NHEJ Repair,” 10-1-11 to 9-30-16. Direct costs per annum $250,000. PI- R. Hromas.
UFCC Team Science Award, “Targeting DNA Repair for enhancement of Colon Cancer Therapy,” 7-1-13 to 6-30-14, $100,000. PI- R. Hromas. PI- R. Hromas.
Leukemia and Lymphoma Society Idea Award NIA-8995-14, “Preventing leukemogenic translocations,” 7-1-13 to 6-31-14, Direct costs $100,000 per annum (one year only). PI- R. Hromas.
NIH RO1 CA140442 “Transposases in Etoposide Resistance,” Direct costs per Annum $233,000, 6-15-09 to 6-14-13, PI- R. Hromas.
NIH RO1 HL093606 “The Transposase Metnase in Leukemic Decatenation,” Direct costs per annum- $225,000, 7-1-08 to 6-30-12, PI- R. Hromas.
NIH ASERT award, Fellowship for Sergio De Haro, PhD, “Autophagy in DNA repair,” Direct costs $50,000/annum, 7-1-09 to 6-30-12. PI- R. Hromas.
NIH HL093606 Supplement, Fellowship for Sheema Fnu, PhD, Direct costs per annum $50,000, 6-1-09 to 5-30-11, PI- R. Hromas.
NIH PA11959 “Metnase in replication stress,” supports Leyma De Haro in her PhD studies. Direct costs per annum, $26,839. 7-1-08 to 6-30-10. PI- R. Hromas.
Leukemia and Lymphoma Society SCOR “Comprehensive Molecular Technologies for Improved Risk Classification and Therapy,” PI- C. Willman, LLS 7388-06, Project 3- “Biological Models for Novel Outcome Genes in ALL,” PI- R. Hromas, Project 3 direct costs per Annum $210,000, 10-1-05 to 9-30-10.
State of New Mexico, “New Treatments for Inflammatory breast cancer,” $150,000/annum, 7-1-08 to 6-30-10.
NIH RO1 Collaborative Supplement CA100862 “DSB Repair, Recombination, and Genome Stability,” Direct Costs per Annum $100,000, 3-1-05 to 2-28-07, co-PI- R. Hromas (with J. Nickoloff).
NIH T35 HL076595, “Institutional National Research Service Award Hispanic,” Direct Costs per annum $75,000, 10-1-03 to 9-31-08. PI- R. Hromas.
NIH RO1 HL075783, “Hex Regulates Hemangioblast Decisions,” Direct Costs per annum- $250,000, 7-1-04 to 6-30-08. PI- R. Hromas.
NIH RO1 CA 102283 “Oct-4 Regulates Embryonal Carcinoma Differentiation,” 7-1-03 to 6-30-08, Direct Costs per annum- $175,000. PI- R. Hromas.
DOD BCRP Concept Award 0610593, “DNA Decatenation in breast cancer by Metnase,” $75,000 Direct costs, 8-13-06 to 8-13-07. PI- R. Hromas.
NIH RO1 HL66308: “Role of Exodus-2/6Ckine/SLC in GVHD” 7-1-01 to 6-30-06, Direct Costs per annum- $323,425. PI- Hromas.
NIH PO1: “Biology of High Risk Germ Cell Tumors” CA 74295. Program PI- L. Einhorn. Project #1- “The Winged Helix Protein Genesis in Germ Cell Neoplasia,” 9-1-99 to 8-30-03. PI- R. Hromas. Project 1 Direct Costs per annum- $139, 409.
NIH Cancer Center Grant, Regulation of Cell Growth Research Program Leader- R. Hromas. 7-1-99 to 6-30-04. Research Program Direct Costs: $10,250. PI- S. Williams.
Leukemia Society of America, Translational Research Award “Therapeutic potential of DCCL family of Chemokines” 9-1-98 to 8-30-01. Direct costs $100,000 per annum. PI- R. Hromas..
Walther Oncology Center, “Winged helix proteins in germ cell tumors,” 7-1-97 to 6-31-04, Direct costs $86,000 per annum. PI- R. Hromas.
NIH RO1 HL48914: "Hematopoietic role of the zinc finger gene MZF-1," 7-1-97 to 6-30-02. Direct costs $212,606 per annum for 5 years. PI- R. Hromas.
Leukemia Society of America Scholar award: started 7-1-94 to 6-30-99, Direct Costs per annum $40,000.
NIH R29 HL 48914: "Hematopoietic role of the zinc finger gene MZF-1," 7-1-92 to 6-30-97. Direct Costs $70,000 per annum. PI- R. Hromas.
Basic Science Research Grant, Indiana University Medical Center, 7-1-91 to 6-30-92, $22,123. PI- R. Hromas.
NIH Research Hematology Fellowship #HL07093-15, 7/1/89-6/30/90, University of Washington, Seattle, Washington Direct costs: $28,400.
Associate Investigator Career Development Award, "Trans-Acting-Factors Regulate the Kappa Immunoglobulin Enhancer", VA Award #103.808, 7/1/87-6/30/88, University of Iowa, Iowa City, Iowa. Direct costs: $34,000. PI- R. Hromas.
NIH Research Hematology Fellowship #HLO7544-9,10, "Thrombosis and Hemostasis", 7/1/85-6/30/87, University of Iowa, Iowa City, Iowa. Direct costs: $24,200 per year.
-
Service
School
EDUCATIONAL CURRICULUM DEVELOPMENT
LCME Data Collection Instrument coordinating editor, UT Health San Antonio, 2018
University of Florida LCME Self Study, organized Internal Medicine self-study section, member of the Faculty Development Committee, 2014-15.
Supervised Internal Medicine medical student curriculum renovation to organ-based modules, University of Florida College of Medicine, 2012-3.
Developed and presented DNA Repair and Acute and Chronic Leukemia curriculum for the first year medical students at the University of New Mexico, 2007-9.
Authored Pocket Hematology-Oncology for University of New Mexico medical students and residents, 2003, 2nd edition 2006.
Designed and wrote UME and GME curriculum for the medical student and resident Hematology-Oncology clinical rotations at the University of New Mexico, including self-assessment exams, 2003.
Director for the Hematology/Oncology section of the sophomore medical student Introduction to Clinical Medicine (personally gave all 12 lectures). Designed novel curriculum and wrote entire course book, Course X601 at Indiana University, 1999-2003.
Instructing Internal Medicine residents and Hematology/Oncology fellows during two months as Staff Physician on the Bone Marrow Transplant Unit, and during a weekly hematology clinic at Indiana University, 1990-2003.
Designed and taught a biochemistry course on the Molecular Basis of Human Disease (B503) for first year medical students (weekly for 3 months, 24 hours total class time) 1992-4 at Indiana University.
Team teaching the medical student biochemistry course (B800), one lecture on the molecular origins of leukemia at Indiana University, 1990-2.
Institutional
MENTORING
Post-doctoral Research Fellows
Mary Lou Meyer, MD, 1992-3
David Xu, MD, 1992-5
Mary Cavalier, MD 2000-3
Evelyn Guo, MD, 2001-3
Bowman Award, Best Post-Doctoral Research at Indiana University, 2002
Shangming Zhang, MD 2001-3
Elizabeth Williamson, PhD 2003-5
Kimi Kong, PhD, 2005-2010
Katie Rasila, MD, 2005-6
Justin Wray, PhD, 2007-11
Sheema Fnu, PhD, 2008-12
Leah Damiani, PhD, 2008-11
Mario Benevenitez, MD 2008-11
Sudha Singh, PhD, 2009-11
Sergio De Haro, PhD, 2009-11
Ilan Shamagum, PhD, 2009-11
George Cain, PhD, 2009-10
Grace Wu, PhD, 2009-16
Brian Reinert, PhD, 2011-16
Xuili Cong, PhD, 2011-2012
Aruna Jaiswal, PhD, 2011-13
Bhavita Patel, PhD, 2014-2018
Sudhir Rai, PhD, 2017- 2019
Gayathri Srinivasan, PhD, 2017-2021
Guangcun Huang, PhD, 2018-2021
Ming Yang, MD, 2022-2024
Manh Tien Tran, PhD, 2022-present
Medical Student Research Fellows
Tim Johnston 1992
Alpina Deasi, 1993
Irene Huang, 1993
Brent Hollenbeck, 1994
Michael Sha, 1994
Jon Bielfield, 1994
Greg Montgomery, 1995
Mark Rosenthal, 1995
Matt Hufford, 1996
Adrian Butler, 1997
PhD Graduate Students (Dissertation Major Advisor on each)
David Mack 1996-2003
Kent Christopherson II 1997-2001
Yong-Hao Hou 1998-2002
Trevor Starnes 1999-2002
Walther Award for Best Graduate Student Research at Indiana University, 2002
David Haines 2000-3
Leyma De Haro, 2007-2010
Jason Rogers, 2010-11
Gayathri Srinivasan, 2013-2017
Dominic Arris, 2022-2025
Nhat Nguyen, 2023-present
ASH Graduate Student Awards
Kent Christopherson, 1999
Yong-Hao Hou, 1999
Trevor Starnes, 2001
Medical Student Faculty Advisor
David Breitweiser, 1994
David Chang, 1995
Michael Sha, 1996
Rod Robinson, 1996
David Bowman, 1997
Soupan Wu, 1998
Danielle Peoni, 2000
Stephanie Jeske, 2002
Jeremy Rogers, 2002
Jared Basham, 2002
Justin Wray, 2009
Undergraduate Student Research Projects
Trish Hufford, 1993
Karina Hill, 2004
Dorothy Cuylear, 2004-5
Leah Martinez, 2005-7
Ben Abeyta, 2006-7
Amanda Gonzales, 2008
Sean Chester, 2008
Will Pham, 2009
Thesis Committee Member
Jill Sutton, Developmental Biology
Burt Webb, Microbiology/Immunology
Melissa Bowker-Kinley, Biochemistry
Stacey Nelson, Microbiology/Immunology
Marcus Fields, Microbiology/Immunology
Faculty Mentored
Ed Chan, MD- “AML1 mutations in secondary acute myeloid leukemia,” 2002-3,
Director of Hematologic Neoplasia Clinical Trials, Eli Lilly
Kathy Miller, MD- “Anti-angiogenic agents in breast cancer therapy,” 2001-2, DoD grant
Assistant to tenured Professor, Indiana University
David Potter, MD- “Role of Calpain in metastasis.” 2001-3, NIH RO1,
Assistant to tenured Professor, Indiana University
Luis Padilla-Paz, MD- “HPV in cervical oncogenesis.” 2003-4
Ian Rabinowitz, MD- “Mutations in human AML.” 2003-4, “Directing Oncology Out- patient Clinics,” 2006-7
Chief of Hematology-Oncology, UNM, 2011
Rebecca Chan, MD- “Hemangioblast Development,” 2002-4, NHLBI RO1,
Assistant to tenured Professor of Pediatrics, Indiana University.
Richard Dahl, PhD- “Lineage decisions in myelopoiesis,” 2004-7
Obtained ACS, LLS grants, then tenured faculty position at Notre Dame
Elizabeth Williamson, PhD- “End joining DNA repair,” 2005-8
Now Research Professor UT Health San Antonio, 2018-present
Dave Garcia, MD- “Genetics of the Coumadin Response in Cancer Patients,” 2006-8,
Director of the Coumadin Clinic, UNM, 2006
Coagulation Director, University of Washington, 2013
Edward Libby, MD- “Creating an in-patient BMT Unit”
Associate Director Myeloma Program, Fred Hutchinson Cancer Center, 2011
Kanwaldeep Rasila, MD- “Novel therapy for NHL,” 2007-9
Director of Hematologic Malignancies, Sutter Medical Group
Claire Verschraegen, MD- “Minority Community Clinical Oncology Program,”
NCI MB-CCOP PI at UNM 2007
Chief of Hematology-Oncology at University of Vermont, 2011
Chief of Oncology at Ohio State University, 2018.
Richard Crowell, MD- “DNA repair differences in minorities with lung cancer,” 2007
Chief of Pulmonary Medicine, UNM
Richard Lauer, MD- “Oncology Executive Medical Director,” 2007-2008,
Oncology Medical Director, UNM, named to ASCO Committee on Practice, 2010
Dennie Jones, Jr., MD- “Chromatin changes in bronchodysplasia progression,” 2007-8
Chief of Oncology and Deputy Director, University of Kentucky Cancer Center, 2011
Chief of Thoracic Oncology at DFCI outreach clinics, 2014
Amy Tarnower, MD- “Directing Value-Based Oncology Out-patient Clinics,” 2008
Julie Bauman, MD- “Inhibiting DNA repair to enhance chemotherapy,” 2009-10
Chief of Head and Neck Oncology, University of Pittsburgh, 2012
Chief of Hematology-Oncology, University of Arizona, 2016
Sudha Singh, PhD- “The role of c1orf124 in trans-lesion DNA repair,” 2011-13
Tenure-track Assistant Professor, University of New Mexico, 2013
Monte Shaheen, MD- “Pso4 in DNA Repair,” 2009-10
Obtained NHLBI K01
Sarah Glover, MD- “Cytokine initiation of IBD,” 2011-14
Tenured Assistant to full Professor, Independent funding, UF
David Reisman, MD- “Chromatin remodelers in lung oncogenesis,” 2012-14
Associate Professor, UF, Started biotechnology firm, joined community practice
Aruna Jaiswal, PhD- “Alternative pathways for base excision repair,” 2013-15
Research Associate Professor, UT Health San Antonio, 2018- present
Silvia Tornaletti, PhD- “Base excision repair,” Res. Assistant Professor, UF, 2012-15
Gurjit Sidhu, PhD- “Sister chromatid exchange,” Res. Asst. Professor, UF 2015- 2018
Kimi Kong, PhD- “EEPD1 in replication fork repair in BRCA1/2 mutant cancers” NCI RO1, 2023
Tenure track Assistant Professor, UT Health San Antonio, 2023-present
Hispanic and Native American Summer Research Program NIH T35 PI
Ten undergraduates each summer 2004-present, placed in UNM laboratories, those in my lab listed above under Undergraduate Student Research Projects
Professional
INTRAMURAL SERVICE
Vice Chair, Hospital Operating Board, UT Health Multispecialty Research Hospital, Sept 2021-Present
144 beds focused on novel therapies in oncology, neurology and neurosurgery, orthopedics and surgical subspecialties for diseases prevalent in south Texas
Greenfield construction, opened Dec 2024
Chaired programming and design committees
Recruited CEO and C-suite
Co-supervised construction
Co-supervised CEO and budget
Co-Chair, Executive Committee for UT Health Science Center San Antonio integration under the University of Texas San Antonio, Aug 2024- Feb 2025
Created plan to implement UT Board of Regents directive to merge under UT San Antonio
Defined relevant task forces
Reviewed task force assignments and output
Coordinated UT Health’s SACSCOC, LCME, CCNE, CODA and other accreditation approval applications for merger
Co-Coordinated communications, merging finances, research administration merger, and new organizational structure
Merged leadership structure under UT San Antonio, Feb 1, 2025
Chair, Planning Committee for Discovery Park, 2024
Public-Private partnership for pharmaceutical and technology development and commercialization
750,000 sf over 5 buildings
Housing basic science for target discovery, biochemical and AI-driven screening, medicinal chemistry, formulation, non-GLP PK/PD/toxicity/metabolism
Chair, Payor Committee, 2022-present
Supervised negotiations for all clinical contracts
Including commercial, Medicaid and managed Medicare payors
Reviewed performance of each contract annually
Founding Chair, Regional Physicians Network Accountable Care Organization Operating Board, 2018-present
Hispanic-focused, value-based ACO with 25+ community physician groups
Recruited and trained replacement Chair, R. Leverence
Chair, Executive Board, Medical Services Research and Development Plan, 2018-2023, Feb 2025-present
After merger with UT San Antonio, the clinical enterprise will keep the UT Health brand
Most trusted healthcare brand in city, based on San Antonio Express-News surveys
Governs the Long School of Medicine clinical faculty practice plan
Clinical departmental Chairs and clinical Institute Directors constitute Board
Projected FY25 revenues $1.05 B, up from $550 M in FY18
30 clinic sites, up from 17 in FY18
Projected patient encounters FY25 are 2.6 M, up from 1.6 M in FY18
Recruited and trained successor (acting Dean F. Cigarroa, Feb, 2024- Feb, 2025)
Chair, Executive Board, University Physicians Group, 2018-2023
Held UT Health’s Epic license and multiple value-based clinical contracts
Dissolved into the above UT Health Multispecialty Research Hospital’s Board, 2023
Member, Executive Committee, UT Health San Antonio, 2018-Present
Chair when acting President, Feb 2024- Feb 2025
Coordinated UT Health San Antonio efforts in co-founding CAST-Med High School, 2019
With San Antonio Independent School District
Lower income area of the city
Health professions pipeline high school
Named the UT Health representative to their Board
UF College of Medicine, Promotion and Tenure Committee, Vice Chair and Chair-elect, 2016-17
UF Health Shands Hospital Capital Committee Co-Chair, 2016-17
UF Health Cancer Center Genomics and Epigenomics Research Program Leader, 2015-17
Chair, Search Committee, Department of Neurology Chair, 2015
New Chair On-boarding Program, UF College of Medicine, 2014-17
Co-conceived of program and co-created curriculum with M. Limacher
UF Health Information Technology Governance Committee, 2014-17
Chair, State of Florida Cancer Pre-eminence Coordinating Committee, 2014-15
Co-Directed the Joint Oncology Program Management Committee, 2013-2015
UF Health and Orlando Health oncology partnership
UF College of Medicine Medical Student Curriculum Renovation
Chair for Internal Medicine curricula, 2013-14
Risk Management Coordinator, Internal Medicine Services, UF Health, 2011-17
UF Health Payor Committee (contract negotiations for clinical reimbursement), 2011-17
UF Health Executive Board, 2012-17
Health system board which oversaw Shands Teaching Hospital operations (~$2.5 B enterprise in FY18)
Quality and Safety Oversight Sub-Committee
System-wide quality improvement initiatives
Vice President, Florida Clinical Practice Association 2011-2017
Faculty clinical practice plan for UF College of Medicine
Personal efforts were on maximizing physician efficiency and productivity and maximizing revenue cycle
UF College of Medicine Clinical Executive Committee, 2011-17
UF College of Medicine Compensation Committee, Vice Chair, 2011-16
UF College of Medicine Committee of Chairs, 2011-17
Chair, Clinical Research Committee, University of New Mexico Cancer Center, 2008-11
Recruited and trained replacement, M. Royce
Director, Clinical Trials Office, University of New Mexico Cancer Center, 2008-11
38 FTE
>330 open trials annually
>400 interventional trial accruals annually
Recruited and trained successor, M. Royce
Member, University of New Mexico Health Science Center Faculty Practice Organization Executive Committee, 2006-7
Recruited and trained successor, R. Lauer
Member, University of New Mexico Health Science Center Post-Doctoral Fellowship Steering Committee, 2007-2009
Member, Chair of Pathology Search Committee, University of New Mexico School of Medicine,2007-8
Member, Research Strategic Planning Committee, University of New Mexico Health Science Center, 2005-11
Director of Oncology, Lovelace Health System, 2005-8
Contracted with University of New Mexico for oncology services
Recruited and trained successor, A. Tarnower
Chair, Cancer Committee for ACOS certification, Lovelace Health System, 2005-8
Physician and Patient Satisfaction Strategic Planning Committee, University of New Mexico Health Science Center, 2004
Director, University of New Mexico Cancer Center Out-Patient Clinic, 2004-8
Trained successor, I. Rabinowitz
Deputy Director, University of New Mexico Cancer Center, 2003-11
Co-wrote all research narratives and Core descriptions and obtained first NCI P30 Cancer Center Support Grant at University of New Mexico
Member, Department of Internal Medicine Executive Committee, University of New Mexico School of Medicine, 2003-11
Oncology Physician-in-Chief, University of New Mexico Hospital, 2003-8
Created first BMT unit
Recruited and trained BMT Director, E. Libby
Supervised the Hematology/BMT floor and the Oncology floor of UNM Hospital
Floor charge nurses co-reported to this position
Recruited and trained Oncology Physician-in-Chief successor, R. Lauer
Medical Executive Committee, University of New Mexico Health Science Center, 2003-6.
Chair, Cancer Committee, University of New Mexico Health Science Center, 2003-2008.
Recruited and trained replacement, R. Lauer
Deputy Director, Indiana University Cancer Center, 2002-3
Wrote one research program narrative and edited grant
Obtained first ever P30 Cancer Center Support Grant for Indiana University
Research Program Director: Regulation of Cell Growth, Indiana University Cancer Center, 1997-2003
Member, Institutional Animal Care and Utilization Committee, Indiana University 1997- 2002
Seminar Coordinator, Indiana University Cancer Center, 1995-2002
Member, Medical Student Research Committee, Indiana University, 1995-2003
Member, Institutional Biosafety Committee, Indiana University, reviewer for human gene therapy protocols, 1994-2002
Indiana University Microbiology/Immunology Chair Search Committee, 1995
PROFESSIONAL ORGANIZATIONS
2023-present Association of Academic Health Centers
2018-2023 Association of American Medical Colleges Council of Deans
2014-present American Clinical and Climatologic Association
2012-present Association of American Physicians
2011-present Association of Professors of Medicine
2005-present American College of Physicians
2002-present American Society of Clinical Investigation
2000-present American Society of Clinical Oncology
1991-2008 International Society for Experimental Hematology
1991-present American Society for Hematology
1985-present American Association for the Advancement of Science
1985-1993 American Federation for Clinical Research
1983-present Alpha Omega Alpha National Medical Honor Society
EXTRAMURAL PROFESSIONAL ACTIVITY
Liaison Committee on Medical Education Executive Board, elected full member, 2019-2022
Survey team member for LCME accreditation at 9 medical schools
Chaired 6 of these site visit survey teams
UT Health San Antonio led city of San Antonio and Bexar county COVID-19 response
Nominated and co-supervised Infectious Disease experts who led city and county pandemic efforts (B. Taylor and R. Berggren)
Served on South Texas Regional Advisory Council (regional hospital council) for pandemic response
Co-led drafting the hospital admission and ICU ethical policies for Southwest Texas Regional Advisory Council
Appointed and supervised pandemic response director for UT Health clinical enterprise (R. Leverence)
AAMC Council of Deans Fellowship Committee and curriculum lecturer, 2019-present
AAMC Lead Serve Learn Program Committee, 2019-2022
Co-Founder and Member, Executive Board, Dialectic Therapeutics, 2018-present
Chair, Scientific Advisory Board
With equity but no compensation, UT Health San Antonio COI management plan in place
No direct fiduciary authority
Recruited investors for developing Bcl-xl/BCL-2 PROTACs for cancer therapy
Licensed IP from University of Arkansas and University of Florida (D. Zhou and G. Zheng)
Co-wrote successful FDA IND application approved 2021
Co-wrote successful Cancer Prevention and Research Institute of Texas (CPRIT) New Product Development grant 2019 ($3 M)
Phase 1 successfully completed at UT Health San Antonio Q4, 2023
Co-wrote successful CPRIT Texas Company grant 2021 ($15 M),
Starting Phase 1b/2 for relapsed ovarian cancer at Dana-Farber Cancer Institute in Q2, 2025
Elected Member, San Antonio Business Forum, 2018-present
Leaders of major corporations and institutions in city
Lobbies city and county on issues facing these institutions
Chair, Scientific Advisory Board, Abfero, 2017-2021
With equity but no compensation, COI management plan completed with sale, 2021
Spin-off from the University of Florida (R. Bergeron) for developing oral iron chelators
Sold in 2021 to Pharmacosmos
No current role, no equity but downstream royalties if drug approved
Samuel Waxman Cancer Research Foundation Executive Board, 2016-2018
Joint Advisory Board, Gainesville Select-Shands Long Term Acute Care Hospital, 2015-2017
Medical Executive Board, Munroe Regional Medical Center Hospital, 2014
Leukemia and Lymphoma Society Grant Review Committee, 2014, 2015, 2016, 2017
Scientific Advisor, Medosome Biotec, LLC (without compensation or equity), 2015-2018,
Supported founding of the LLC
Private-University partnership for faculty SBIR development at the University of Florida
Successfully submitted 8 SBIRs from UF faculty
Coordinated with Department of Pediatrics, S. Rivkees who founded the LLC
American Society of Hematology National Media Spokesperson, 2013,14
American Society of Hematology Revenue Committee, 2013,14
American Society of Hematology advocate to US Congress for medical research funding, 2011-14
Co-Chair, American Society of Hematology Bridge Funding Task Force, 2012
Association of Professors of Medicine, Program Committee, 2011-15
Alliance for Academic Internal Medicine Program Committee, 2012-4
Editor-in-Chief, American Society of Hematology Research Agenda 2012, 2015
Chair, Scientific Affairs, American Society of Hematology, 2011-14
Chair, Highlights of the American Society of Hematology, New York, 2011
Chair, Highlights of the American Society of Hematology, Washington DC, 2011
Member, Radiation Therapeutics and Biology (RTB) Study Section, NIH, 2011-15
Scientific Co-Chair, American Society of Hematology Annual Meeting, 2010
Scientific Advisory Board, Northshore Biotechnology (without compensation or equity), 2010-2013
Chair, Small Meeting Oversight Committee, American Society of Hematology, 2010-12
Chair, NHLBI SEP Vascular Biology and Hematology, 2010
Executive Advisory Board, Yale University Center of Excellence in Hematology, 2010
Program Committee, American Society of Hematology annual meeting, 2009-15
Chair, NHLBI RFA Review Panel, Blood Stem Cell Niche, 2009
Chair, NHLBI SEP Hematopoietic Stem Cell Regulation, 2009
Chair, NHLBI P01 AG033564 Review Panel, 2009
Invited Speaker, NCI APRC Workshop on Innovative Cancer Research Collaborations, 2008
Member, ASH Scholars Study Section, 2003, 2008, 2009, 2010.
Chair, Hematopoiesis (HP) Study Section, NIH, 2007-08; Full Member 2003-2007
Invited Panel Member, NIH Center for Scientific Review Committee, “Directions for the Next Decade;” 11/07, revised RO1/R21 format.
NCI P30 CCSG Review Committee, Roswell Park Cancer Institute, 9/07
NCI P30 CCSG Review Committee, Memorial Sloan Kettering Cancer Center; 5/07
Chair, Cell Cycle and Hematopoiesis Abstract Review Committee, American Society of Hematology, 2006
State of New Mexico Cancer Plan Steering Committee, 2004-2010 (recruited and trained replacement, T. Stewart)
Chair, Leukemia and Immunology Review Group, American Cancer Society, 2003-4, Member 2000-2004
Chair, Education Committee, New Mexico Cancer Care Alliance, 2003-2008
Lance Armstrong Foundation National Scientific Advisory Board, 2003-2005
Member, NCI CCSG Review Panel, Wake Forest Cancer Center, 2000
Co-Chair, Infrastructure Committee, NCI Progress Review Group on Hematologic Malignancies, 2000
Tumor Biology Subcommittee, American Society of Clinical Oncology, 2000-2002
Editorial Board, BLOOD, 1997-2002
Scientific Subcommittee for Myeloid Biology, American Society of Hematology, 1997-2002
Editorial Board, STEM CELLS, 1997-2002
Founder and Presiding Co-Organizer (with J. Licht), Workshop on Myeloid Development annual meeting
Orlando (1996)
Miami (1998)
San Francisco (2000), Philadelphia (2002)
San Diego (2003, 2004)
Atlanta (2005)
Orlando (2006)
Atlanta (2007)
San Francisco (2008)
New Orleans (2009)
Orlando (2010, fully subscribed at 1200 attendees)
San Diego (2011, fully subscribed at 2000 attendees)
Co-recruited and trained replacements, L. Zon and A. Rosmarin
International Society of Experimental Hematology Gene Expression Symposium Chair, 1994.
Councilor, Midwest Blood Club, 1995-1998
Member, NASA Microgravity Cell Science Study Section, 1995-2000
Community
Cade Museum Board of Trustees, Gainesville, FL, 2016- 2018
Celebrating innovation in Florida and the invention of Gatorade
The Cade created multiple pipeline science programs for high school students
Founder and primary capitalizer, Waves Micro-Credit Bank, Kumasi, Ghana, 2008
Ghana nationalized all microcredit banks, 2012
Volunteer and Speaker, Leukemia and Lymphoma Society, 2003-present
Keynote speaker, Albuquerque, NM annual walkathon, 2006
Keynote speaker for Florida state annual banquet, Orlando, 2013, 2015
Indianapolis youth soccer physicals, 1995-1998
Indianapolis inner city free health screening clinics, 1997-1999
-
Publications
BOOK AUTHORSHIP
“Einstein’s Boss: 10 Rules for Leading Genius,” Hromas R, Hromas C. HarperCollins Leadership series, May 15, 2018. ISBN: 9780814439159. Translated into >20 languages.
BOOK CHAPTERS
Hromas, R. and Putt, D. The origins of leukocyte neoplasia: In: Diagnostic Hematology, B. Rodek, ed. W. B. Saunders, pgs. 401-409, Philadelphia, 1995.
Putt, D., and Hromas, R. The therapy of leukocyte neoplasia.in Diagnostic Hematology, B. Rodek, ed. W.B. Saunders, pgs. 411-424, Philadelphia, 1995.
Hoffman, R., Silverstein, M., and Hromas, R. Essential thrombocytosis. In: Hematology: Basic Principles and Practice, second edition, R. Hoffman, ed., Churchill-Livingston, pgs. 1174-1183, New York, 1994.
Christopherson, K, and Hromas, R. Endothelial chemokines in autoimmune disease. In Current Pharmaceutical Design – Autoimmunity, Bentham Science Publishers, 2003.
Willman, C. and Hromas, R. Genomic alterations and chromosomal aberrations in human cancer. In Cancer Medicine version 7, BC Decker, 2006.
Chan RJ, Hromas R, Yoder MC. The role of Hex in hemangioblast and hematopoietic development. Methods Mol Biol. 330:123-33, 2006.
Dahl R and Hromas R. Transcription Factors in Normal and Malignant Hematopoiesis. In Hematology: Basic Principles and Practice. 4th Edition (Ed. R. Hoffman et al.). Churchhill Livingstone, 2008.
Fekrazad H, Hromas R, Lauer R. The Biology and Treatment of Metastatic Testicular Cancer. Cancer Metastasis (Ed. D. Welch et al). Cambridge, NY, 2010.
Williamson EA, Wray JW, Bansal P, Hromas R. Overview of the histone codes for DNA repair. Prog Mol Biol Transl Sci. 2012;110:207-27.
Cogle C, Meacham A, and Hromas R. Regulation of gene expression, transcription, splicing, and RNA metabolism. In Hematology: Basic Principles and Practice. 6th Edition (Ed. R. Hoffman et al.). Churchhill Livingstone, 2013.
PATENTS/INVENTIONS
Patents
Functional characterization of the CC chemokine-like molecules encoded by Molluscum Contagiosum virus types 1 and 2
Treatment of myeloproliferative disease with Exodus chemokine
Novel bifunctional Metnase inhibitors and related compounds
Use of mir223 as a cancer therapeutic and method for treating cancer using the same
Antibodies Specific to CCL21 and Methods of Use
RESEARCH ARTICLES
Hromas, R.A., Markel, D., and Scholes, V.: Flow microfluoremetric analysis of the cell cycle phase cytotoxicity of Ara-C. Res. Comm. Chemical Pathol. Pharmacol. 30: 365-368, 1980.
Hromas, R.A., Hutchins, J., Markel, D., and Scholes, V.: Flow cytometric analysis of the effects of Ara-C on the chronobiology of bone marrow DNA synthesis. Chronobiologia 8: 369-373, 1981.
Hromas, R.A., Barlogie, B., and Swartzendruber, D.: Selective protection by anguidine of normal versus transformed cells against cytosine arabinoside and adriamycin. Cancer Res. 43: 1135-1137, 1983.
Hromas, R.A., Barlogie, B., Swartzendruber, D., and Drewinko, B.: Potentiation of DNA-reactive antineoplastic agents and protection against S-phase specific agents by anguidine. Cancer Res. 44: 3070-3073, 1983.
Hromas, R.A., and Murray, L.J.: Bone marrow in the acquired immundeficiency syndrome. Annals of Internal Medicine 101: 877, 1984.
Hromas, R.A., Shrigley, J., and Murray, L.J.: Clinical and pathologic comparison of young adult women with hepatocellular carcinoma with and without exposure to oral contraceptives. Am. J. Gastroneterol 9: 479-485, 1985.
Hromas, R.A., and Yung, W.-K.A.: Anguidine potentiates cis-platinum in human brain tumor cells. J. Neuro. Oncol. 3: 343-348, 1986.
Hromas, R.A., and Van Ness, B.: Nuclear factors bind to regulatory regions of the mouse kappa immunoglobulin gene. Nucl. Acids Res. 14: 4837-4848, 1986.
Hromas, R.A., Andrews, P.A., Murphy, M.P., and Burns, C.P.: Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Letters 34: 9-13, 1987.
Hromas, R.A., North, J.A., and Burns, C.P.: Decreased cisplatin uptake by resistant L1210 leukemia cells. Cancer Letters 36: 197-201, 1987.
Hromas, R.A., Pauli, V., Marcuzzi, A., Lafrenz, D., Nick, H., Stein, J., Stein, G., and Van Ness, B.: Inducible DNA-protein interactions of the murine kappa immunoglobulin enhancer in intact cells: comparions with in vitro interactions. Nucleic Acids Res. 16: 953-967, 1988.
Gailani, D., Cadwell, F.J., O'Donnell, P.S., Hromas, R.A., and Macfarlane, D.E.: Absence of phorbol ester-induced down-regulation of myc protein in the phorbol ester-tolerant mutant of HL-60 promyelocytes. Cancer Research 49: 5329-5333, 1989.
Nelms, K., Hromas, R.A., and Van Ness, B.: Identification of a second inducible DNA-protein interaction in the kappa immunoglobulin enhancer. Nucleic Acids Res. 18: 1037-1043, 1990.
Shoemaker, S., Hromas, R.A., and Kaushansky, K.: Regulation of the IL-3 gene by AP-1 and a novel transcription factor, NF-IL3-A. Proc. Natl. Acad. Sci. USA, 87: 9650-9653, 1990.
Radford, J.E., Chen, E., Hromas, R., and Ginder, G.D.: Cell-type specificity of interferon-gamma-mediated HLA Class I gene transcription in human hematopoietic tumor cells. Blood 77: 2008-2015, 1991.
Hromas, R., Collins, S., Hickstein, D., Hagen, F., O'Hara, P., Raskind, W., Deaven, L., and Kaushansky, K.: A retinoic-acid responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J. Biol. Chem. 266: 14183-14187, 1991.
Hromas, R., Collins, S., Raskind, W., Deaven, L., and Kaushansky, K.: Hem-1, a potential membrane protein, with expression restricted to blood cells. Biochimica et Biophysica Acta 1090: 241-244, 1991.
Bavisotto, L., Kaushansky, K., Lin, N., and Hromas, R.: Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro. J. Exp. Med. 174: 1097-1101, 1991.
Hromas, R., Zon, L., and Friedman, A.: Hematopoietic transcription regulators and the origins of leukemia. Critical Reviews in Oncology/Hematology 12: 167-190, 1992.
Cornetta, K, Tricot, G, Broun ER, Hromas, R, Srour, E, Hoffman, R, Anderson, WF, Moen, RC, and Morgan RA. Clinical Protocol: Retroviral mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia. Human Gene Therapy 3:305-318, 1992.
Hromas, R., May, W., Denny, C., Moore, J., Maki, R., Raskind, W., and Klemsz, M. The ETS oncogene FLI-1 is located at chromosome 11q24 and has an aberrant transcript in neuroepithelioma. Biochem. Biophys. Acta. 1172:155-158, 1993.
Klemsz, M., Maki, R., Papayannopoulou, T., Moore, J., and Hromas, R. Characterization of the ETS oncogene Fli-1. J. Biol. Chem. 268:5769-5773, 1993.
Hromas, R, Moore, J, Johnston, T, Socha, C, and Klemsz, M. Drosophila Forkhead homologues are expressed in a lineage-restricted manner in human hematopoietic cells. Blood 81:2854-2859, 1993.
Hromas, R., Radich, J., and Collins, S. PCR cloning of a novel homeobox gene (PRH) preferentially expressed in hematopoietic cells. Biochem. Biophys. Res. Commun. 195:976-983, 1993
Moore, J., Boswell, S., Burgess, G., Hoffman, R., and Hromas, R. H-ras over-expression inhibits a random apoptotic nuclease in hematopoietic cells. Leukemia Res. 17:703-709, 1993.
Hromas, R., Orazi, O., Neiman, R., Moore, J., Maki, R., Van Beveran, C., and Klemsz, M. Hematopoietic lineage and stage-restricted expression of the ETS oncogene family member PU.1. Blood 82:2998-3004, 1993.
May, W., Lessnick, S., Braun, B., Klemsz, M., Lewis, B., Lunsford, L., Hromas, R., and Denny, C. Ewing's Sarcoma EWS/FLI fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13:7393-7398, 1993.
Morris, J., Hromas, R., and Rauscher, F. III. Characterization of the DNA-binding properties of the myeloid zinc finger gene MZF1: Two independent DNA binding domains recognize two DNA sequences with a common G-rich core. Mol. Cell. Biol. 14:1786-1795, 1994.
Klemsz, M., Hromas, R.*, Raskind, W., Bruno, E., and Hoffman, R. PE-1, a novel ETS oncogene family member, localizes to chromosome 1q21-23. Genomics 20:291-294,1994.*- Corresponding author
Broun, ER, Wheat, JL, Kneebone, P, Sundblad, K, Hromas, R, Tricot, G.: A randomized trial of the addition of gram positive prophylaxis to standard antimicrobial prophylaxis in patients undergoing bone marrow transplantation. Antimicrob. Agents and Chemotherapy 38:576-579, 1994.
Hromas, R, and Klemsz, M. The ETS oncogene family in development, proliferation, and neoplasia. Int. J. Hematol. 59:257-265, 1994.
Hromas, R., Cornetta, K, Srour, E, Blanke, C., and Broun, E.R. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell depleted bone marrow transplantation. Blood 84:1689-1690, 1994.
Hromas, R., Clark, C., Blanke, C., Tricot, G., Cornetta, K., Heddermen, A., and Broun, E. R. Failure of ribavirin to clear adenovirus infections in T-cell Depleted allogeneic bone marrow transplantation. Bone Marrow Transplantation 14:663-4, 1994.
Hromas, R, Klemsz, M, Hufford, T, Huang, I, Desai, A, and Hoffman, R. Drosophila forkhead homologues are expressed in CD34+HLA-DR- primitive hematopoietic precursors. Leukemia and Lymphoma 15:439-444, 1994.
Hromas, R., Morris, J., Cornetta, K., Berebitsky, D., Davidson, A., Sha, M., Sledge, M., and Rauscher, F., III. Aberrant Expression of the myeloid zinc finger gene, MZF-1, is oncogenic. Cancer Res. 55:3610-3614, 1995.
Hromas, R, and Costa, R. The hepatocyte nuclear factor-3/Forkhead transcription regulatory family in development, inflammation and neoplasia. Crit. Rev. Oncol./Hematol. 20:129-140, 1995.
Baumgartner, S., Martin, D., Chiquest-Ehrismann, R., Orazi, A., Sutton, J., Desai, A., Huang, I., Kato, K., and Hromas, R. The HEM family of proteins: Tissue-specific membrane-associated proteins expressed from Drosophila through mammals with essential functions in oogenesis. J. Molec. Biol. 251:41-49, 1995.
Broun, E.R., Sridhara, R., Sledge, G., Loesch, D., Kneebone, P., Hanna, M., Hromas, R., Cornetta, K., and Einhorn, L.H. Tandem autotransplantation for the treatment of metastatic breast cancer. J. Clin. Oncol. 13:2050-2055, 1995.
Blanke, C., Clark, C., Broun, E.R., Tricot, G., Cunningham, I., Cornetta, K., Hedderman, A., and Hromas, R. Evolving pathogens in allogeneic bone marrow transplantation. Am. J. Med. 99:326-328, 1995.
Morris, J., Rauscher, F., III, Davis, B., Klemsz, M., Xu, D., Tenen, D., and Hromas, R. The myeloid zinc finger gene MZF-1 regulates the CD34 promoter in vitro. Blood 86:3940-3947, 1995.
Hromas, R., Davis, B., Rauscher, F, III, Tenen, D., Xu, D., and Morris, J. Hematopoietic transcriptional regulation by the myeloid zinc finger gene MZF-1. Curr. Topics Micro. Immunol. 211:159-164, 1995.
Broun, E.R., Sledge, G., Loesch, D., Cornetta, K., Hromas, R., Kneebone, P., Lottich, C., Schmidt, T., and Einhorn, L. Two cycles of high dose chemotherapy with autologous bone marrow support for patients with locally advanced breast carcinoma. Breast J. 1:308-314, 1995.
Broun, E.R., Nichols, C., Mandanas, R., Slazman, D., Turns, M., Hromas, R., Cornetta, K., and Einhorn, L. Dose escalation study of high dose carboplatinum and etoposide with autologous bone marrow support in patients with recurrent or refractory germ cell tumors. Bone Marrow Transplantation 16:353-358, 1995.
Hoffman, S., Hromas*, R., Amemiya, C., and Mohrenweiser, H. The location of MZF-1 at the telomere of human chromosome 19 makes it vulnerable to degeneration in aging cells. Leukemia Res. 20:281-283, 1996. *-Corresponding author.
Hromas, R., Boswell, H. S., Shen, R., Burgess, G., Davidson, A., Cornetta, K., and Robertson, K. Forced expression of the myeloid zinc finger gene MZF-1 inhibits apoptosis and promotes oncogenesis in IL-3-dependent FDCP.1 cells. Leukemia 10:1049-1050, 1996.
Cornetta, K., Srour, E., Moore, A., Davidson, A., Broun, R., Hromas, R., Moen, R., Morgan, R., Rubin, L., Anderson, W.F., Hoffman, R., and Trciot, G. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Human Gene Therapy 7:1323-1329, 1996.
Sutton, J., Costa, R., Field, L., Xu. D., Largaespada, D., Fletcher, C., Jenkins, N., Copeland, N., Klemsz, M., and Hromas, R. Genesis [now FoxD3], a winged helix transcriptional repressor with expression restricted to embryonic stem cells. J. Biol. Chem. 271:23126-23133, 1996.
Gharpure, V., Rubin, L., Amlin, J., Emanuel, D., Schroeder, W., Davidson, A., Hromas, R., and Cornetta, K. Lymphocytosis of donor origin in cerebrospinal fluid, and marrow aplasia after donor leukocyte infusion for EBV-lymphoproliferative disease. Bone Marrow Transplant. 18:221-224, 1996.
Rigden, J., Cornetta, K., Srour, E., Broun, E.R., Hromas, R., Baute, J., Hilton, J., Cox, E., Rubin, L., Gonin, R., and Tricot, G. Minimizing graft rejection in allogeneic T-cell depleted bone marrow transplantation. Bone Marrow Tranaplantation 18:913-919, 1996.
Broun, E.R., Nichols, C., Gize, G., Cornetta, K., Hromas, R., Schacht, B., and Einhorn, L. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:1605-1610, 1997.
Hromas, R., Gray, P., Chantry, D., Godiska, R., Krathwohl, M., Fife, K., Aronica, S., Cooper, S., Broxmeyer, H., and Klemsz, M. Cloning and characterization of Exodus [now CCL20], a novel beta chemokine. Blood 89:3315-3322, 1997.
Orazi, A., Hromas, R., Neiman, R., Greiner T., Lee, C., Rubin, L., Haskins, S., Heerema, N., Gharpure, G., Abonour, R., Srour, E., and Cornetta, K. Post-transplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am. J. Clin. Pathol. 107:419-429, 1997.
Zhang, D., Hromas, R., Licht, J., and Tenen, D. Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519, 1997.
Hromas, R., Kim, C., Klemsz,M., Krathwohl, M., Fife, K., Cooper, S., Schnizlein-Bick, C., and Broxmeyer, H. Isolation and characterization of Exodus-2 [now CCL21], a novel C-C chemokine with a unique 37 amino acid carboxy terminal extension. J. Immunology 159:2554-2558, 1997 (Cutting Edge).
Krathwohl, M., Hromas, R., Brown, D., Broxmeyer, H., and Fife, K. Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc. Natl. Acad. Sci. USA 94:9875-9880, 1997.
Hromas, R., Hufford, M., Sutton, J., Xu, D., Li, Y., and Lu, L. PLAB, a novel bone morphogenetic protein. Biochem. Biophys. Acta 1354:40-44, 1997.
Cornetta, K.,Gharpure, V., Mills, B., Hromas, R., Broun, E.R., Traycoff, C.M., Hanna, M., Wyman, N., Danielson, C., Gonin, R., Kunkel, L., Oldham, F., and Srour, E. Rapid engraftment after allogeneic transplantation using CD34-enriched marrow cells. Bone Marrow Transplant 21:65-71, 1998.
Xu, D., Yoder, M., Sutton, J, and Hromas, R. Forced expression of Genesis [now FoxD3], a winged helix transcriptional repressor isolated from embryonic stem cells, blocks granulocytic differentiation of 32D myeloid cells. Leukemia 12:207-212, 1998.
Robertson, K., Hill, D., Kelley, M., Crum, B., Van Epps, S., Srour, E., Rice, S., and Hromas, R. The myeloid zinc finger gene MZF-1 delays retinoic acid-induced apoptosis and differentiation in myeloid cells. Leukemia 12:690-698, 1998.
Braun, S., Mantel, C., Rosenthal, S., Cooper, S., Liu, L., Robertson, K., Hromas, R., and Broxmeyer, H. A positive effect of p21 cip1/waf1 in the colony formation from murine myeloid progenitor cells as assessed by retroviral-mediated gene transfer. Blood Cells Molec Dis 24:138-148, 1998.
Cripe, L. and Hromas, R. Malignant Disorders of megakaryocytes. Semin. Hematol. 35:200-9, 1998.
Abonour, R. Scott, K., Kunkel, L., Robertson, M., Hromas, R., Graves, V., Lazarides, E., Cripe, L., Gharpure, V., Traycoff, C., Mills, B., Srour, E., and Cornetta, K. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant. 22:957-63, 1998.
Hromas, R., Broxmeyer, H., Kim, C., Nakshatri, H., Christopherson, K., Azam, M., and Hou, Y.-H. Cloning of BRAK [now CXCL14], a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem. Biophys. Res. Commun. 255:703-6, 1999.
Broxmeyer, H., Kim, C., Cooper, S., Hangoc, G., Hromas, R., and Pelus, L. Effects of CC, CXC, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Annals New York Acad. Sci. 872:142-163, 1999.
Hromas, R. Broxmeyer, H.E., Kim, C., Christopherson, K., and Hou, Y.-H. Isolation of ALP [now CCL27], a novel divergent murine CC chemokine with a unique carboxy terminal extension. Biochem. Biophys. Res. Commun.258:737-740, 1999.
Hromas R, Ye H, Spinella M, Dmitrovsky E, Xu D, Costa RH. Genesis [now FoxD3], a winged helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model. Cell Tissue Res 297:371-82, 1999.
Christopherson K 2nd, Brahmi Z, Hromas R. Regulation of naive fetal T-cell migration by the chemokines Exodus-2 and Exodus-3 [now CCL19,CCL21]. Immunol Lett 69:269-73, 1999.
Topcu Z, Mack DL, Hromas R, and Borden K. The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control. Ooncogene 18:7091-7100, 1999.
Hromas R, Cripe L, Hangoc G, Cooper S, and Broxmeyer H. The Exodus sub-family of CC chemokines [now CCL19-21] inhibits the proliferation of CML progenitors. Blood 95:1506-1508, 2000.
Robertson MJ, Williams BT, Christopherson K 2nd, Brahmi Z, Hromas R. Regulation of Human Natural Killer Cell Migration and Proliferation by the Exodus Subfamily [now CCL19-21] of CC Chemokines. Cell Immunol. 199:8-14, 2000.
Braun, S, Chen, K, Foster, R, Kim, C, Hromas, R, Kaplan, M, Broxmeyer, H, Cornetta, K. The CC chemokine CKb-11/MIP-3b/ELC/Exodus 3 [now CCL19] mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunology 164: 4025-4031, 2000.
R Abonour, D A Williams, L Einhorn, K M Hall, J Chen, J Coffman, C M Traycoff, A Bank, I Kato, M Ward, S D Williams, R Hromas, M J Robertson, F O Smith, D Woo, B Mills, E F Srour & K Cornetta. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nature Medicine 6:652-658, 2000.
Robert Hromas, Rinah Shopnick, Hani George Jumean, Charles Bowers, Marileila Varella-Garcia and Kathleen Richkind. A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95:4011-4013, 2000.
Kathleen Richkind, Robert Hromas*, C. Lytle, D. Crenshaw, J. Velasco, S. Roherty, Jayanthi Srinivasiah, and Marileila Varella-Garcia. Identification of two novel translocations which disrupt the AML1 gene. Cancer Genetics and Cytogenetics, 122:141-143, 2000. *- Corresponding author.
Robert Hromas, Tracey Busse, Audra Carroll, David Mack, Rinah Shopnick, Dong-Er Zhang, Harikrishna Nakshatri, and Kathleen Richkind. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood 97:2168-2170, 2001.
Gaboli, M, Kotski, P., Guirrieri, C., Cattoretti, G., Ronchetti, S., Cordon-Cardo, C., Broxmeyer, H., Hromas, R., and Pandolfi, P. MZF-1 controls cell proliferation and tumorogenesis. Genes and Development 15:1625-30, 2001.
Christopherson, K., and Hromas, R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 19:388-396, 2001.
Hromas, R, Shopnick, R, Jumean, HG, Bowers, C, Varella-Garcia, M, Richkind, K. Radiation-induced leukemia. Blood 97:1897-1898, 2001.
Christopherson, K., Campbell, J., and Hromas, R. Transgenic expression of the chemokine CCL21 in T-cells disrupts T-cell migration. Blood 98: 3562-3568, 2001.
Starnes, T., Robertson, M., Sledge, G., Kelich, S., Nakshatri, H., Broxmeyer, H., and Hromas, R. IL-17F, a novel cytokine selectively expressed in activated T-cells and monocytes, regulates angiogenesis and endothelial cells cytokine production. J. Immunology, Cutting Edge, 167:4137-4140, 2001.
Guo, Y, Costa, R, Ramsey, H, Starnes, T, Vance, G, Robertson, K, Kelley, M, Reinbold, R, Scholer, H, and Hromas, R. The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc. Natl. Acad. Sci. USA. 99:3663-7, 2002.
Christopherson K 2nd, Campbell JJ, Travers JB, and Hromas R. Low Molecular Weight Heparins Inhibit CCL21-Induced T-Cell Adhesion and Migration. J. Pharmacol. Exp. Ther. 302:1-6, 2002.
Starnes, T., Broxmeyer, H., and Hromas, R. IL-17D, a novel member of the IL-17 family, simulates cytokine production, and inhibits myelopoiesis. J. Immunol. 169:642-6, Cutting Edge, 2002.
Hromas R. Cutting the head off chemokines. Blood 100:1110, 2002.
Broxmeyer, H., Cooper, S., and Hromas, R. The chemokine CCL21 protects normal marrow progenitors against cytotoxic chemotherapy. Cancer Chemother. Pharmacol. 50:163-6. 2002.
Humphreys TL, Schnizlein-Bick CT, Katz BP, Baldridge LA, Hood AF, Hromas RA, Spinola SM. Evolution of the Cutaneous Immune Response to Experimental Haemophilus ducreyi Infection and Its Relevance to HIV-1 Acquisition. J Immunol. 69:6316-23, 2002.
Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP Jr, Wood L, Cornetta K. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res. 8:3383-93, 2002.
Mack DL, Leibowitz DS, Cooper S, Ramsey H, Broxmeyer HE, Hromas R. Down-regulation of the myeloid homeobox protein Hex is essential for normal T-cell development. Immunology 107:444-51, 2002.
Humphreys TL, Schnizlein-Bick CT, Katz BP, Baldridge LA, Hood AF, Hromas RA, Spinola SM. Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition. J Immunol. 169:6316-23, 2002.
Christopherson KW, Hood AF, Travers JB, Ramsey H, Hromas RA. Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood 101:801-6, 2003.
George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung SH, Shen J, Finch DE, Kelley MR, Einhorn LH. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 21:113-22, 2003.
Ramsey, H., Zhang, D.E., Richkind, K., Burcoglu-O’Ral, A., Hromas, R. Fusion of AML1/Runx1 to Copine VIII, a Novel Member of the Copine Family, in an Aggressive Acute Myelogenous Leukemia with t(12;21) Translocation. Leukemkia 17:1665-6, 2003.
Hromas, R. Cracking chemokine paradigms: Inhibition of idiopathic pneumonia syndrome. Blood 101:3344, 2003.
Guo, Y., Chan, R., Bort, B., Zaret, K., Yoder, M., Hromas, R. The Homeoprotein Hex is Required for Hemangioblast Differentiation. Blood 102:2428-37, 2003. (Featured in Inside Blood).
Christopherson, K, and Hromas, R. Endothelial Chemokines in Auto-immune Disease. Current Pharmaceutical Design 10(2): 145-154, 2004.
Ramsey H, Christopherson K, Hromas R. Forced expression of AML1-AMP19, a fusion transcript generated from a radiation-associated t(19;21) leukemia, blocks myeloid differentiation. Leuk Res. 28:863-8, 2004.
Guo Y, Einhorn L, Kelley M, Hirota K, Yodoi J, Reinbold R, Scholer H, Ramsey H, Hromas R. Redox regulation of the embryonic stem cell transcription factor oct-4 by thioredoxin. Stem Cells. 22:259-64, 2004.
Hou YH, Srour EF, Ramsey H, Dahl R, Broxmeyer HE, Hromas R. Identification of a human B-cell/myeloid common progenitor by the absence of CXCR4. Blood. 105:3488-92, 2005. (Featured in Inside Blood).
Chan EM, Comer EM, Brown FC, Richkind KE, Holmes ML, Chong BH, Shiffman R, Zhang DE, Slovak ML, Willman CL, Noguchi CT, Li Y, Heiber DJ, Kwan L, Chan RJ, Vance GH, Ramsey HC, Hromas RA. AML1-FOG2 Fusion Protein in Myelodysplasia. Blood. 105:4523-6, 2005.
Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 Oct;46(10):1477-87.
Suk-Hee Lee, Masahiko Oshige, Stephen Durant, Kanwaldeep Kaur Rasila, Elizabeth Williamson, Heather Ramsey, Lori Kwan, Jac A. Nickoloff, and Robert Hromas. The SET domain protein Metnase mediates foreign DNA integration and links integration to NHEJ repair. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A. 102:18075-80, 2005.
Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A. 102:17763-8, 2005.
Bibb J, Hromas R, Rabinowitz I. A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid. J Clin Oncol. 23:8911-3, 2005.
Hal E. Broxmeyer, Trevor Starnes, Heather Ramsey, Scott Cooper, Richard Dahl, Elizabeth Williamson, and Robert Hromas. The IL-17 cytokine family members are inhibitors of human hematopoietic progenitor proliferation. Blood, Jul 2006; 108: 770.
Broxmeyer HE, Pelus LM, Kim CH, Hangoc G, Cooper S, Hromas R. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C. Exp Hematol. 2006 Aug;34(8):1069-77.
Starnes T, Rasila KK, Robertson MJ, Brahmi Z, Dahl R, Christopherson K, Hromas R. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 2006 Aug;34(8):1101-5.
Roman Y, Oshige M, Lee Y-J, Goodwin K, Georgiadis MM, Hromas RA, and Lee S-H. Biochemical characterization of a SET and transposase fusion protein, metnase: Its DNA binding and DNA cleavage activity. Biochemistry 2007 Oct 9;46(40:11369-11376.
Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, DIotti R, Milton K, Pujara K, Landers T, Dev Batish S, Morales J, Schindler D, Hanenberg H, Hromas R, Levran O, Auerbach AD. Genetic heterogeneity among Fanconi anemia heterozygotes and Risk of Cancer. Cancer Res. 2007 Oct 1;67(19):9591-6.
Guo Y, Mantel C, Hromas RA, Broxmeyer HE. Oct 4 is Critical for Survival/Antiapoptosis of Murine Embryonic Stem Cells Subjected to Stress. Effects Associated with STAT3/Survivin. Stem Cells. 2008 Jan;26(1):30-4.
110. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH. Human PSO4 is a Metnase (SETMAR) binding partner that regulates Metnase' function in DNA repair. J Biol Chem. 2008 Apr 4;283(14):9023-30.
111. Nickoloff JA, De Haro LP, Wray J, Hromas R. Mechanisms of leukemia translocations. Curr Opin Hematol. 2008 Jul;15(4):338-45.
112. Williamson EA, Farrington J, Martinez L, Ness S, O'Rourke J, Lee SH, Nickoloff J, Hromas R. Expression levels of the human DNA repair protein metnase influence lentiviral genomic integration. Biochimie. 2008 Sep;90(9):1422-6.
113. Hromas R, Wray J, Lee SH, Martinez L, Farrington J, Corwin LK, Ramsey H, Nickoloff JA, Williamson EA.Metnase interacts with DNA Ligase IV and increases the accuracy of NHEJ repair. DNA Repair (Amst). 2008 Dec 1;7(12):1927-37.
114. Williamson EA, Rasila KK, Corwin LK, Wray J, Beck BD, Severns V, Mobarak C, Lee SH, Nickoloff JA, Hromas R. The SET and transposase domain protein Metnase enhances chromosome decatenation: Regulation by automethylation. Nucleic Acids Res. Oct;36(18):5822-31. (Cover).
115. Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, Nickoloff JA, Hromas R. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.PLoS ONE. 2009;4(4):e5323.
116. Kong KY, Williamson EA, Rogers JH, Tran T, Hromas R, Dahl R. Expression of SCL in mesoderm rescues hematopoiesis in the absence of Oct-4. Blood. 2009 Mar 25. [Epub ahead of print] Jul 2;114(1):60-3 (Cover).
117. Wray J, Williamson EA, Lee S-H, Libby E, Willman CL, Nickoloff JA, Hromas R. Metnase mediates chromosome decatenation in acute leukemia cells. Blood, 2009, May 15 [epub ahead of print] Aug 27;114(9):1852-8 (Cover, featured in Inside Blood).
118. Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radke I, Downing JR, Fleming MD, Macconaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT. Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. Mol Cell Biol. 2009 Nov;29(21):5911-22.
119. Wiggins C, Nelson H, Harlan L, Stevens JL, Willman C, Libby E, and Hromas R. Age disparity in the dissemination of imatinib for treatment of chronic myeloid leukemia. American Journal of Medicine, 2010 Aug; 123(8):764-773, 2010.
120. Shaheen M, Williamson E, Nickoloff J, Lee SH, Hromas R. Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation. Genetica. 2010 May;138(5):559-66.
121. Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe LD. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.Bone Marrow Transplant. 2010 Aug;45(8):1300-8.
122. Wray J, De Haro L, Williamson E, and Hromas R. The transposase domain protein Metnase/SETMAR suppresses chromosomal translocations. Genes Chromosomes Cancer, 200:184-90, 2010.
123. De Haro, L; Wray, J; Williamson, E; Durant, S; Corwin, L; Gentry, A; Osheroff, N; Lee, S‑H; Hromas, R; Nickoloff, J. Metnase Promotes Restart and Repair of Stalled and Collapsed Replication Forks. Nucleic Acids Res, Sep 1;38(17):5681-91, 2010.
124. Beck B, Lee S, Hromas R, and Lee S-H. Regulation of Metnase’s TIR binding activity by its partner, Pso4. Archives Biochem Biophys, 2010 Jun 15;498(2):89-94.
124. Fnu S, Williamson EA, De Haro LP, Brenneman M, Wray J, Shaheen M, Radhakrishnan K, Lee SH, Nickoloff J, and Hromas R. Methylation of Histone H3 Lysine 36 Enhances DNA Repair by Non-Homologous End-Joining. Proc Natl Acad Sci USA epub Dec 27, 2010.
125. Shaheen M, Shanmugam I, Hromas R. The Role of PCNA Posttranslational Modifications in Translesion Synthesis. J Nucleic Acids. 2010 Aug 11;2010 pii: 761217.
126. Williamson EA, Boyle TJ, Raymond R, Farrington J, Verschraegen C, Shaheen M, Hromas R. Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP) (2) against cancer colony forming cells. Invest New Drugs. 2012 Feb;30(1):114-20.
127. Libby E, Hromas R. Dismounting the MDR horse. Blood. 2010 Nov 18;116(20):4037-8.
128. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood. 2011 Jun 9;117(23):6074-82.
129. Beck BD, Lee SS, Williamson E, Hromas RA, Lee SH. Biochemical characterization of Metnase's endonuclease activity and its role in NHEJ repair. Biochemistry. 2011 May 24;50(20):4360-70.
130. Allen C, Ashley AK, Hromas R, Nickoloff JA. More forks on the road to replication stress recovery. J Mol Cell Biol. 2011 Feb;3(1):4-12.
131. Hromas R, Williamson EA, Fnu S, Lee YJ, Park SJ, Beck BD, You JS, Laitao A, Nickoloff JA, Lee SH. Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart. Oncogene. 2012 Jan 9. doi: 10.1038/onc.2011.586.
132. Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, Labarbera DV. Neoamphimedine Circumvents Metnase-Enhanced DNA Topoisomerase IIα Activity Through ATP-Competitive Inhibition. Mar Drugs. 2011;9(11):2397-408.
133. Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH, Hromas R. Targeting the Transposase Domain of the DNA Repair Component Metnase to Enhance Chemotherapy. Cancer Res. 2012 Dec 1;72(23):6200-6208.
134. Hromas R, Abkowitz JL, Keating A. Facing the NIH Funding Crisis: How Professional Societies Can Help. JAMA. 2012 Dec 12;308(22):2343-4.
135. Wray J, Williamson EA, Singh SB, Wu Y, Cogle CR, Weinstock DM, Zhang Y, Lee SH, Zhou D, Shao L, Hauer-Jensen M, Pathak R, Klimek V, Nickoloff JA, Hromas R. PARP1 is required for chromosomal translocations.Blood. 2013 May 23;121(21):4359-65.
136. Jaiswal AS, Panda H, Pampo CA, Siemann DW, Gairola CG, Hromas R, Narayan S. Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia. 2013 Apr;15(4):454-60.
137. Mohapatra S, Yannone SM, Lee SH, Hromas RA, Akopiants K, Menon V, Ramsden DA, Povirk LF. Trimming of damaged 3' overhangs of DNA double-strand breaks by the Metnase and Artemis endonucleases. DNA Repair (Amst). 2013 Jun 1;12(6):422-32.
138. Williamson EA, Hromas R. Repressing DNA Repair to Enhance Chemotherapy: Targeting MyD88 in Colon Cancer. J Natl Cancer Inst. 2013 Jul 3;105(13):926-7.
139. Byrne M, Wray J, Reinert B, Wu Y, Nickoloff J, Lee SH, Hromas R, Williamson E. Mechanisms of oncogenic chromosomal translocations. Ann N Y Acad Sci. 2014 Mar;1310:89-97.
140. Kim HS, Chen Q, Kim SK, Nickoloff JA, Hromas R, Georgiadis MM, Lee SH. The DDN Catalytic Motif is required for Metnase Functions in NHEJ Repair and Replication Restart. J Biol Chem. 2014 Apr 11;289(15):10930-8.
141. Libby E, Garcia D, Quintana D, Fekrazad MH, Bauman J, Ebaid A, Hromas R, Rabinowitz I, Wiggins C. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. 2014 Dec;55(12):2850-7.
142. Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Al Masri A, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia. 2014 Oct;28(10):1978-87.
143. Rath A, Hromas R, De Benedetti A. Fidelity of end joining in mammalian episomes and the impact of Metnase on joint processing. BMC Mol Biol. 2014 Mar 22;15(1):6.
144. Abbas M, Shanmugam I, Bsaili M, Hromas R, Shaheen M. The role of the human Psoralen 4 (hPso4) complex in replication stress and homologous recombination. J Biol Chem. 2014 May 16;289(20):14009-19.
145. Williamson EA, Wu Y, Singh S, Byrne M, Wray J, Lee SH, Nickoloff JA, Hromas R. The DNA repair component Metnase regulates Chk1 stability. Cell Div. 2014 Jul 9;9:1.
146. Shanmugam I, Abbas M, Ayoub F, Mirabal S, Bsaili M, Caulder EK, Weinstock DM, Tomkinson AE, Hromas R, Shaheen M. Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. J Biol Chem. 2014 Aug 15;289(33):22739-48.
147. Schmit JM, Turner DJ, Hromas RA, Wingard JR, Brown RA, Li Y, Li MM, Slayton WB, Cogle CR. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep. 2015 Apr 3;4(1):24-7.
148. Jaiswal AS, Panda H, Law BK, Sharma J, Jani J, Hromas R, Narayan S. NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells. PLoS One. 2015 May 1;10(5):e0123808.
149. Kim HS, Kim SK, Hromas R, Lee SH. The SET Domain Is Essential for Metnase Functions in Replication Restart and the 5' End of SS-Overhang Cleavage. PLoS One. 2015 Oct 10; (10):e0139418.
150. Wu Y, Lee SH, Williamson EA, Reinert BL, Jaiswal AS, Srinivasan G, Patel B, Brantley A, Zhou D, Shao L, Pathak R, Hauer-Jensen M, Singh S, Kong K, Wu X, Cho JH, Xia F, Kim HS, Beissbarth T, Gaedcke J, Burma S, Nickoloff JA, Hromas R. EEPD1 promotes DNA end resection, replication fork repair and genome stability during replication stress. PLOS Genetics 11(12): e1005675, 2015.
151. Chun C, Wu Y, Lee SH, Williamson EA, Reinert BL, Jaiswal AS, Nickoloff JA, Hromas RA. The homologous recombination component EEPD1 is required for genome stability in response to developmental stress of vertebrate embryogenesis. Cell Cycle 15(7): 957-62, 2016.
152. Narayan S, Jaiswal AS, Law BK, Kamal MA, Sharma AK, Hromas RA. Interaction between APC and Fen1 during breast carcinogenesis. DNA Repair (Amst). 2016 May;41:54-62.
153. Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. PLoS One. 2016 Jan 19;11(1):e0147230.
154. Lebedyeva IO, Oliferenko AA, Oliferenko PV, Hromas RA, Neubert JK, Caudle RM, Wickersham J, Castleman WL, Altschuler GL, Ostrov DA, Dennis Hall CD, Katritzky AR. Ionic conjugates of lidocaine and sweeteners as better tasting local anesthetics for dentistry. Journal of Materials Chemistry B 43(3): 8492-8498, 2015.
155. Leverence R, Nuttall R, Palmer R, Segal M, Wood A, Shuster J, Brantly M, Hromas R. Using Organizational Philosophy to Create a Self-Sustaining Compensation Plan Without Harming Academic Missions. Academic Medicine 2017 Aug;92(8):1133-1137.
156. Hromas R, Williamson E, Lee SH, Nickoloff J. Preventing the Chromosomal Translocations that Cause Cancer. Trans Am Clin Climatol Assoc. 127:176-195, 2016.
157. Kim HS, Williamson EA, Nickoloff JA, Hromas RA. Lee, S-H. Metnase Mediates Loading of Exonuclease 1 onto Single Strand Overhang DNA for End Resection at Stalled Replication Forks. J. Biol Chem 292(4):1414-1425, 2017.
158. Kim HS, Lee SH, Wu Y, Williamson EA, Reinert BL, Jaiswal AS, Nickoloff JA, Hromas RA. Endonuclease EEPD1 Is a Gatekeeper for Repair of Stressed Replication Forks. J. Biol Chem 292(7):2795-2804, 2017.
159. Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R. Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059.
160. Srinivasan G, Sidhu GS, Williamson E, Jaiswal AS, Najmunissa N, Wilcoxen K, Jones D, George TJ, Hromas RA. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemo Pharmacol. 80(4):861-867, 2017.
161. Narayan S, Jaiswal AS, Sharma R, Nawab A, Duckworth LV, Law BK, Kaye-Zajac M, George TJ, Sharma J, Sharma AK, Hromas RA. NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget. 8(34):57246-57264, 2017.
162. Hromas R, Kim H-S, Sidhu G, Williamson EA, Jaiswal A, Totterdale TA, Nole J, Lee S-H, Nickoloff JA, Kong KY. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells. Breast Cancer Research 19:122-136, 2017.
163. Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017 Nov 27;7(12):634
164. Shao L, Feng W, Cang J, Wang X, Williamson EA, Li Y, Schajnovitz A, Scadden D, Mortensen LJ, Lin CP, Li L, Downing J, Zhou D, Hromas R. The WAVE2 scaffold Hem-1 is required for the transition of fetal liver hematopoiesis to the bone marrow. Nature Communications 2018 Jun 18;9(1):2377.
165. Hromas R, Jameson L, Schwenk T, Zimmerman E, Good M. National Survey: What a Medical School Chair Wants from their Dean. J. HealthCare Leadership 2018; 10: 33–44.
166. Abkowitz JL, Hromas R. Approaching the crisis in medical research funding: an important role for nonprofit organizations and medical societies. Blood Adv. 2018 Apr 24;2(8):846-847.
167. Abkowitz JL, Hromas R. Confronting the Research Funding Crisis: Medical Societies' Role in Filling the Gap. Acad Med. 2018 Jul;93(7):961-962.
168. Wang W, Daley JM, Kwon Y, Xue X, Krasner DS, Miller AS, Nguyen KA, Williamson EA, Shim EY, Lee SE, Hromas R, Sung P. A DNA nick at Ku-blocked double-strand break ends serves as an entry site for exonuclease 1 (Exo1) or Sgs1-Dna2 in long-range DNA end resection. J Biol Chem. 2018 Sep 17. pii: jbc.RA118.004769.
169. Zhao W, Wiese C, Kwon Y, Hromas R, Sung P. The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination. Annu Rev Biochem. 2019 Jun 20;88:221-24.
170. Todorova PK, Fletcher-Sananikone E, Mukherjee B, Kollipara R, Vemireddy V, Xie XJ, Guida PM, Story MD, Hatanpaa K, Habib AA, Kittler R, Bachoo R, Hromas R, Floyd JR, Burma S. Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. Cancer Res. 2019 Jul 15;79(14):3749-3761.
171. Liang F, Miller AS, Longerich S, Tang C, Maranon D, Williamson EA, Hromas R, Wiese C, Kupfer GM, Sung P. DNA requirement in FANCD2 deubiquitination by USP1-UAF1-RAD51AP1 in the Fanconi anemia DNA damage response. Nat Commun. 2019 Jun 28;10(1):2849.
172. Srinivasan G, Williamson EA, Kong K, Jaiswal AS, Huang G, Kim HS, Schärer O, Zhao W, Burma S, Sung P, Hromas R. MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers. Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17438-17443.
173. Jaiswal AS, Williamson EA, Srinivasan G, Kong K, Lomelino CL, McKenna R, Walter C, Sung P, Narayan S, Hromas R. The splicing component ISY1 regulates APE1 in base excision repair. DNA Repair (Amst). 2020 Feb;86:102769.
174. Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.
175. He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol. 2020 Jul 27;13(1):103.
176. Viswanathan T, Arya S, Chan SH, Qi S, Dai N, Misra A, Park JG, Oladunni F, Kovalskyy D, Hromas RA, Martinez-Sobrido L, Gupta YK. Structural basis of RNA cap modification by SARS-CoV-2. Nat Commun. 2020 Jul 24;11(1):3718.
177. Sharma N, Speed MC, Allen CP, Maranon DG, Williamson E, Singh S, Hromas R, Nickoloff JA. Distinct roles of structure-specific endonucleases EEPD1 and Metnase in replication stress responses. NAR Cancer. 2020 Jun;2(2):zcaa008.
178. Nickoloff JA, Sharma N, Allen CP, Taylor L, Allen SJ, Jaiswal AS, Hromas R. Roles of homologous recombination in response to ionizing radiation-induced DNA damage. Int J Radiat Biol. 2021 Aug 4:1-12. doi: 10.1080/09553002.2021.1956001.
179. Capitano ML, Jaiswal A, Broxmeyer HE, Pride Y, Glover S, Amlashi FG, Kirby A, Srinivasan G, Williamson EA, Mais D, Hromas R. A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease. PLoS One. 2021 Jul 1;16(7):e0252805.
180. Neubert JK, Oliferenko AA, Oliferenko PV, Emets SV, Ostrov DA, Altschuler GI, Calkins J, Wickersham J, Hromas R, Lebedyeva IO. Sweet-Tasting Ionic Conjugates of Local Anesthetics and Vasoconstrictors.Molecules. 2021 Feb 12;26(4):983.
181. Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.Metabolism. 2020 Sep;110:154297.
182. Rajamanickam S, Park JH, Subbarayalu P, Timilsina S, Bates K, Yadav P, Nirzhor SSR, Eedunuri V, Mohammad TA, Jung KH, Onyeagucha B, Abdelfattah N, Benevides R, Lee G, Chen Y, Vadlamudi R, Brenner A, Kaklamani V, Jatoi I, Kuhn J, Hromas R, Gupta YK, Kaipparettu BA, Arbiser JL, Rao MK. Targeting aberrant replication and DNA repair events for treating breast cancers. Commun Biol. 2022 May 24;5(1):493.
183. Yadav P, Subbarayalu P, Medina D, Nirzhor S, Timilsina S, Rajamanickam S, Eedunuri VK, Gupta Y, Zheng S, Abdelfattah N, Huang Y, Vadlamudi R, Hromas R, Meltzer P, Houghton P, Chen Y, Rao MK. M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. Cancer Res. 2022 May 16;82(10):1872-1889.
184. Kornepati AVR, Boyd JT, Murray CE, Saifetiarova J, de la Peña Avalos B, Rogers CM, Bai H, Padron AS, Liao Y, Ontiveros C, Svatek RS, Hromas R, Li R, Hu Y, Conejo-Garcia JR, Vadlamudi RK, Zhao W, Dray E, Sung P, Curiel TJ. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Cancer Res. 2022 Jun 6;82(11):2156-2170.
185. Qi S, Mota J, Chan SH, Villarreal J, Dai N, Arya S, Hromas RA, Rao MK, Corrêa IR Jr, Gupta YK. RNA binding to human METTL3-METTL14 restricts N6-deoxyadenosine methylation of DNA in vitro. Elife. 2022 Jan 21;11:e67150. doi: 10.7554/eLife.67150.
186. Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 Nov 25;12(1):6896.
187. Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19.
188. Fletcher-Sananikone E, Kanji S, Tomimatsu N, Di Cristofaro LFM, Kollipara RK, Saha D, Floyd JR, Sung P, Hromas R, Burns TC, Kittler R, Habib AA, Mukherjee B, Burma S. Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence. Cancer Res. 2021 Dec 1;81(23):5935-5947.
189. Nickoloff JA, Sharma N, Taylor L, Allen SJ, Hromas R. The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination. Front Genet. 2021 Sep 27;12:748033.
190. Nickoloff JA, Sharma N, Taylor L, Allen SJ, Hromas R. Nucleases and Co-Factors in DNA Replication Stress Responses. DNA (Basel). 2022 Mar;2(1):68-85.
191. Hromas R, Srinivasan G, Yang M, Jaiswal A, Totterdale TA, Phillips L, Kirby A, Khodayari N, Brantley M, Williamson EA, Kong KY. BRCA1 mediates protein homeostasis through the ubiquitination of PERK and IRE1. iScience. 2022 Nov 19;25(12):105626.
192. Jaiswal A, Jaiswal A, Williamson EA, Gelfond J, Zheng G, Zhou D, Hromas R. Resistance to the BCL-XL Degrader DT2216 in T-cell Acute Lymphoblastic Leukemia is Rare and Correlates with Decreased BCL-XL Proteolysis. Cancer Chemother. Pharmacol. 08 Nov, 2022.
193. Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 2023 Jan 2;9(1):1.
194. Wang X, Shao L, Richardson KK, Ling W, Warren A, Krager K, Aykin-Burns N, Hromas R, Zhou D, Almeida M, Kim H-N. Hematopoietic cytoplasmic adaptor protein Hem1 promotes osteoclast fusion and bone resorption in mice. J. Biol Chemistry. 2023 Feb 299 (2): 102841.
195. Jaiswal AS, Kim H-S, Schärer OD, Sharma N, Williamson EA, Srinivasan G, Phillips L, Kong K, Arya S, Misra A, Dutta A, Gupta Y, Walter CA, Burma S, Narayan S, Sung P, Nickoloff JA, Hromas R. EEPD1 Promotes Repair of Oxidatively-Stressed Replication Forks. NAR Cancer. 2023 Jan 18;5(1):zcac044. doi: 10.1093/narcan/zcac044.
196. Kwon Y, Rösner H, Zhao W, Selemenakis P, He Z, Kawale AS, Katz JN, Rogers CM, Neal FE, Badamchi Shabestari A, Petrosius V, Singh AK, Joel MZ, Lu L, Holloway SP, Burma S, Mukherjee B, Hromas R, Mazin A, Wiese C, Sørensen CS, Sung P. DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation. Nat Commun. 2023 Jan 26;14(1):432. doi: 10.1038/s41467-023-36211-x.
197. Subbarayalu P, Yadav P, Timilsina S, Medina D, Baxi K, Hromas R, Vadlamudi RK, Chen Y, Sung P, Rao MK. The RNA Demethylase ALKBH5 Maintains Endoplasmic Reticulum Homeostasis by Regulating UPR, Autophagy, and Mitochondrial Function. Cells. 2023 Apr 29;12(9):1283.
198. Jaiswal AS, Williamson EA, Jaiswal AS, Kong K, Hromas RA. In Vitro Reconstitutive Base Excision Repair (BER) Assay. Methods Mol Biol. 2023;2701:91-112.
199. Rawal Y, Jia L, Meir A, Zhou S, Kaur H, Ruben EA, Kwon Y, Bernstein KA, Jasin M, Taylor AB, Burma S, Hromas R, Mazin AV, Zhao W, Zhou D, Wasmuth EV, Greene EC, Sung P, Olsen SK. Structural insights into BCDX2 complex function in homologous recombination. Nature. 2023 Jul;619(7970):640-649.
200. Jaiswal AS, Dutta A, Gayathri Srinivasan G, Yuan Y, Zhou D, Shaheen M, Sadideen DT, Kirby A, Williamson EA, Gupta Y, Olsen S, Xu M, Loranc E, Mukhopadhyay P, Pertsemlidis A, Bishop AJR, Sung P, Nickoloff JA, and Hromas R. TATDN2 Resolution of R-Loops is Required for Survival of BRCA1-Mutant Cancer Cells. Nucleic Acids Res. 2023 Nov 11:gkad952. doi: 10.1093/nar/gkad952.
201. Chen S, Srinivasan G, Jaiswal A, Williamson EA, Li L, Arris D, Zhou D, Xu M, and Hromas R. MiR223-3p Promotes Genomic Stability of Hematopoietic Progenitors After Radiation. Experimental Hematology, 2023 Oct 22:S0301-472X(23)01737-X. doi: 10.1016/j.exphem.2023.10.002. Online ahead of print. PMID: 37875176.
202. Nickoloff JA, Jaiswal AS, Sharma N, Williamson EA, Tran MT, Arris D, Yang M, Hromas R. Cellular Responses to Widespread DNA Replication Stress. Int J Mol Sci. 2023 Nov 29;24(23):16903.
203. Wang M, Li W, Tomimatsu N, Yu CH, Ji JH, Alejo S, Witus SR, Alimbetov D, Fitzgerald O, Wu B, Wang Q, Huang Y, Gan Y, Dong F, Kwon Y, Sareddy GR, Curiel TJ, Habib AA, Hromas R, Dos Santos Passos C, Yao T, Ivanov DN, Brzovic PS, Burma S, Klevit RE, Zhao W. Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair. Mol Cell. 2023 Oct 19;83(20):3679-3691.
204. Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A, Ruben EA, Lv Z, Sung P, Hromas R, Zheng G, Zhou D, Olsen SK. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nat Commun. 2024 Mar 29;15(1):2743.
205. Agrawal R, Al-Hiyari S, Hugh-White R, Hromas R, Patel Y, Williamson EA, Mootor MFE, Gonzalez A, Fu J, Haas R, Jordan M, Wickes BL, Mohammed G, Tian M, Doris MJ, Jobin C, Wernke KM, Pan Y, Yamaguchi TN, Herzon SB, Boutros PC, Liss MA. Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer. Eur Urol Oncol. 2024 Nov 14:S2588-9311(24)00245-1. doi: 10.1016/j.euo.2024.10.015. Epub ahead of print. PMID: 39547899.
206. George TJ, Lee JH, DeRemer DL, Hosein PJ, Staal S, Markham MJ, Jones D, Daily KC, Chatzkel JA, Ramnaraign BH, Close JL, Ezenwajiaku N, Murphy MC, Allegra CJ, Rogers S, Zhang Z, Li D, Srinivasan G, Shaheen M, Hromas R. Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms. JCO Precis Oncol. 2024 Dec;8:e2400406. doi: 10.1200/PO-24-00406.
207. Salunkhe S, Daley JM, Kaur H, Tomimatsu N, Xue C, Raina VB, Jasper AM, Rogers CM, Li W, Zhou S, Mojidra R, Kwon Y, Fang Q, Ji JH, Badamchi Shabestari A, Fitzgerald O, Dinh H, Mukherjee B, Habib AA, Hromas R, Mazin AV, Wasmuth EV, Olsen SK, Libich DS, Zhou D, Zhao W, Greene EC, Burma S, Sung P. Promotion of DNA end resection by BRCA1-BARD1 in homologous recombination. Nature. 2024 Oct;634(8033):482-491. doi: 10.1038/s41586-024-07910-2. Epub 2024 Sep 11. PMID: 39261729; PMCID: PMC11539920.
Total citations- 16,079; H Index- 65; i10 Index- 183 as of 1-2-25
Manuscripts after number 16 were produced at Indiana University. Manuscripts after 91 were published at the University of New Mexico. Manuscripts after 128 were published at the University of Florida. Manuscripts after 163 were published at the University of Texas Health Center at San Antonio.